VenomeTech is a spinoff of academic research (University of Nice Sophia Antipolis and CNRS) dedicated to the exploitation of venom compounds for the development of novel therapeutics.

The vision of the company is the valorization by innovative technologies of the immense pharmacological and structural potential of venoms for the development of drugs more potent, and with less side effects.

The mission of the company is to bring into the development pipeline novel molecules for pain, cancer and central nervous diseases. The company thus aims at significantly contributing to the treatment of major diseases for the benefit of patients and society.

VenomeTech is the leader of the VENOMICS european project, gathering a consortium of 8 partners from 5 countries, with the aim of implementing a novel paradigm for venom-based drug discovery.

For more informations, follow the link